The introduction of targeted inhibitors for the mutated oncogenic proteins that drive melanoma onset and aggressiveness, such as BRAF (vemurafenib and dabrafenib), MEK (trametinib and cobimetinib), and c-KIT (imatinib), has improved the durability of treatment response [3]. Here, MAP2K7 is linked to melanoma.